THERAPY DOSSIER · th-a3d9a8d09a59

Neutralising anti-interleukin-17 monoclonal antibody

Biologic · A therapeutic class, not a single molecule; no ChEMBL entity was queried because the source study used a generic neutralising anti-IL-17 antibody without naming a clinical product. CLASS-LEVEL FLAG, recorded knowingly: the 8 recorded trials cover the three marketed IL-17 neutralising antibodies, secukinumab (anti-IL-17A), ixekizumab (anti-IL-17A) and bimekizumab (anti-IL-17A/F). ALL are dermatological or rheumatological (plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa); NONE is a trauma, wound-healing or injury indication, so this entry is class-level translation only, not indication translation. IL-17 RECEPTOR blockers such as brodalumab were excluded because receptor blockade is a different mechanism from ligand neutralisation.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: A therapeutic class, not a single molecule; no ChEMBL entity was queried because the source study used a generic neutralising anti-IL-17 antibody without naming a clinical product. CLASS-LEVEL FLAG, recorded knowingly: the 8 recorded trials cover the three marketed IL-17 neutralising antibodies, secukinumab (anti-IL-17A), ixekizumab (anti-IL-17A) and bimekizumab (anti-IL-17A/F). ALL are dermatological or rheumatological (plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa); NONE is a trauma, wound-healing or injury indication, so this entry is class-level translation only, not indication translation. IL-17 RECEPTOR blockers such as brodalumab were excluded because receptor blockade is a different mechanism from ligand neutralisation.
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 8

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04717466 ↗PHASE4completed

Brain Morphological Changes Accompanied by Effective Biologic Treatments for Psoriasis (Secukinumab)

Psoriasis · Healthy

Enrolment: 20 · Results not recorded

NCT02662985 ↗PHASE3completed

A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis

Psoriatic Arthritis

Enrolment: 166 · Results not recorded

NCT03478787 ↗PHASE3completed

A Multicenter, Randomized, Open Label Study of Risankizumab Compared to Secukinumab for Moderate to Severe Plaque Psoriasis

Psoriasis

Enrolment: 327 · Results not recorded

NCT03025542 ↗PHASE2completed

A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Moderate to Severe Chronic Plaque Psoriasis

Chronic Plaque Psoriasis

Enrolment: 49 · Results not recorded

NCT03099980 ↗EARLY_PHASE1completed

Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

Enrolment: 20 · Results not recorded

NCT04259346 ↗PHASE1completed

Bioequivalence of an Alternate Ixekizumab Formulation Compared to the Commercial Formulation in Healthy Subjects

Healthy

Enrolment: 245 · Results not recorded

NCT06888193 ↗PHASE1recruiting

A Multicenter Open-label, Prospective Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Bimzelx

Plaque Psoriasis · Psoriatic Arthritis · Axial Spondyloarthritis · Hidradenitis Suppurativa

Enrolment: 20 · Results not recorded

NCT03828643 ↗NAcompleted

Secukinumab Efficacy Without the Initial Loading Dose at Weeks 0, 1, 2, 3 and 4 in Patients With Chronic Plaque Psoriasis

Psoriasis Vulgaris

Enrolment: 156 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26100210 ↗2015Reported benefit

Treatment with a neutralising anti-rat interleukin-17 antibody after multiple-trauma reduces lung inflammation.

RatOtherSprague-DawleyFemaleAfter the multiple-trauma model was established

Model: Multiple trauma (polytrauma) model in rats

Neutralisation of interleukin 17 lowered serum interleukin 17 and lung interleukin 17 mRNA and reduced lung tissue inflammation after multiple trauma. No quantitative magnitudes were reported in the abstract.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…

Neutralising anti-interleukin-17 monoclonal antibody